1.
Acta Derm Venereol
; 100(6): adv00077, 2020 Mar 12.
Article
in English
| MEDLINE
| ID: mdl-32115666
Subject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Arthritis, Psoriatic/drug therapy , Colitis/chemically induced , Ileitis/chemically induced , Vasculitis, Leukocytoclastic, Cutaneous/chemically induced , C-Reactive Protein/analysis , Colitis/diagnostic imaging , Diarrhea/chemically induced , Female , Humans , IgA Vasculitis/chemically induced , Ileitis/diagnostic imaging , Middle Aged , Necrosis , Skin/pathology , Tomography, X-Ray Computed , Vasculitis, Leukocytoclastic, Cutaneous/diagnosis
2.
J Crohns Colitis
; 14(4): 538-542, 2020 May 21.
Article
in English
| MEDLINE
| ID: mdl-31589303
ABSTRACT
Tumour necrosis factor-α [TNF-α] inhibitors have revolutionised the management of chronic inflammatory conditions. A number of cutaneous adverse events have been reported with TNF inhibition, including vasculitis. Most reactions are mild and rarely warrant treatment withdrawal. Here we describe a patient with Crohn's disease treated with adalimumab in whom severe multivisceral Henoch-Schönlein purpura developed, including neurological involvement, requiring definitive TNF blocker withdrawal.
Subject(s)
Adalimumab/adverse effects , Crohn Disease/drug therapy , Gastrointestinal Hemorrhage , Glucocorticoids/administration & dosage , IgA Vasculitis , Peripheral Nervous System Diseases , Adalimumab/administration & dosage , Administration, Intravenous , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/adverse effects , Crohn Disease/diagnosis , Dose-Response Relationship, Drug , Electromyography/methods , Endoscopy, Gastrointestinal/methods , Female , Gastrointestinal Hemorrhage/diagnosis , Gastrointestinal Hemorrhage/etiology , Humans , IgA Vasculitis/diagnosis , IgA Vasculitis/etiology , IgA Vasculitis/physiopathology , IgA Vasculitis/therapy , Peripheral Nervous System Diseases/diagnosis , Peripheral Nervous System Diseases/etiology , Severity of Illness Index , Skin/pathology , Treatment Outcome , Tumor Necrosis Factor Inhibitors/administration & dosage , Tumor Necrosis Factor Inhibitors/adverse effects , Young Adult
3.
Acta Derm Venereol
; 98(3): 380-381, 2018 Mar 13.
Article
in English
| MEDLINE
| ID: mdl-29136267
Subject(s)
Autoimmune Diseases/epidemiology , Skin Diseases, Vesiculobullous/epidemiology , Adult , Aged , Aged, 80 and over , Autoantibodies/blood , Autoimmune Diseases/diagnosis , Autoimmune Diseases/therapy , Biomarkers/blood , Female , France/epidemiology , Humans , Incidence , Male , Middle Aged , Prospective Studies , Registries , Skin Diseases, Vesiculobullous/diagnosis , Skin Diseases, Vesiculobullous/therapy , Time Factors
4.
Rev Prat
; 67(3): 299-302, 2017 03 20.
Article
in French
| MEDLINE
| ID: mdl-30657296
